Quick answer
EHL BIO prioritizes strategic alliances at both business and community levels by signing MOUs with organizations like the Icheon Chamber of Commerce and Gyeonggi Dongbu Ginseng Cooperative to promote health and biotechnology innovation. These partnerships expand cell therapy services and ensure safety standards under Korea's Advanced Regenerative Medicine Act.
Key takeaways
- Signed MOUs with community organizations to promote health-related activities.
- Established strategic partnerships with over 25 leading cosmetic and pharmaceutical firms.
- Network of 100+ partner hospitals in Korea for medical knowledge exchange.
- Received Ministerial honors for contributions to advanced regenerative medicine.
Connecting Innovation to Communities and Local Organizations
EHL BIO believes that effective medical innovation should be accessible and beneficial to the community. The company has proactively formed partnerships with local Korean organizations, such as the MOU signed with the Gyeonggi Dongbu Ginseng Cooperative on September 2nd, to develop health promotion projects integrating traditional wisdom with modern technology.
Furthermore, on September 28th, EHL BIO expanded its network to the business sector through an agreement with the Icheon Chamber of Commerce and Industry to conduct joint health promotion activities for members and personnel. These collaborations not only disseminate knowledge about regenerative medicine but also strengthen the regional economic and health ecosystems, supported by a research team of over 85 experts dedicated to improving quality of life.
Business Alliances and Leading Medical Networks
In the industrial and medical service sectors, EHL BIO is recognized as a leader in stem cell and immune cell technology. The company has established strategic alliances with leading cosmetic and pharmaceutical firms such as Korean Colmar, Cosmax, Cosmecca Korea, and Duckwoo Co., Ltd., alongside over 25 other partners. Together, they develop innovative products like klosome and Hermes Exosome premium skin boosters focused on deep skin rejuvenation.
Regarding clinical services, EHL BIO maintains a network of 100+ partner hospitals across South Korea, including top plastic surgery centers like JK, ID, and Yonsei Jayunmi, for knowledge exchange and clinical standard elevation. Possessing GMP-standard production facilities and being the first in Korea to receive CPC (Cell Processing Center) authorization ensures that medical partners can trust the quality and safety of cell therapies used in actual treatments.
Collaboration with businesses and communities is the heart of moving cell therapy innovation from the lab to broadly improving people's quality of life.
Research Collaborations with University Medical Institutions
EHL BIO focuses on proving medical outcomes through rigorous scientific processes via research collaborations with numerous national universities and hospitals, including Chungnam National University Hospital, Dankook University Hospital, Chonnam National University Hospital, and Gangnam Severance Hospital of Yonsei University. These collaborations cover advanced regenerative medicine R&D, from animal studies to human clinical trials.
A significant milestone is being selected for the Korean Fund for Regenerative Medicine (KFRM) to research KDSTEM for chronic kidney disease and ADSTEM for atopic dermatitis, which is now entering Phase 3 clinical trials. Working with top academic institutions allows EHL BIO to gather empirical data confirming precision in immune modulation and tissue regeneration.
Safety Standards and National Certifications
Trust from businesses and communities stems from systematic operational standards. EHL BIO is the first facility in Korea approved as a 'Human Cell Management Business' under the Advanced Regenerative Bio Act, regulated by the MFDS and the Ministry of Health and Welfare. This standard covers cell collection, inspection, and processing within Class 100 facilities to ensure maximum safety for every produced lot.
With a production capacity of 6,000 lots per year and a liquid nitrogen storage system at -196°C, EHL BIO is prepared to be Asia's cell therapy hub. Receiving the 'Minister of Health and Welfare' award in 2024 and the 'Jang Young-shil' award in 2025 confirms success in developing technology for society and tangible innovation.
Frequently asked questions
Does EHL BIO have international collaborations, including in Thailand?
Yes, EHL BIO has a network of 50+ partner hospitals abroad and a dedicated EHL Thailand team to coordinate and provide consultations in Thai for those interested in services in Korea.
What is the purpose of collaborating with chambers of commerce and cooperatives?
To promote the health of community members and organization personnel through regenerative medicine education and access to the company's GMP-standard medical innovations.
Which EHL BIO innovations resulted from beauty industry collaborations?
Skin booster products like klosome and Hermes Exosome, as well as Conditioned Media used in premium cosmetics, developed in partnership with leading Korean cosmetic industry players.
Related conditions
Based on EHL BIO information: EHL BIO · EHL BIO · EHL BIO · EHL BIO · EHL BIO. Each care plan follows an individual EHL assessment.
